{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.3","upperLimit":"99.7","value":"97.5"},{"groupId":"OG001","lowerLimit":"92.7","upperLimit":"98.5","value":"95.6"},{"groupId":"OG002","lowerLimit":"84.7","upperLimit":"96.9","value":"90.8"},{"groupId":"OG003","lowerLimit":"91.3","upperLimit":"95.7","value":"93.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"205"},{"groupId":"OG002","value":"180"},{"groupId":"OG003","value":"498"}],"units":"Participants"}],"description":"To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized on the first day of continuation phase to receive 3500 units/m\\^2 dose of PEG-asparaginase","id":"OG000","title":"TOTXVI PEG 3500"},{"description":"Patients randomized on the first day of continuation phase to receive 2,500 units/m\\^2 dose of PEG-asparaginase","id":"OG001","title":"TOTXVI PEG 2500"},{"description":"Patients who came off study prior to randomization","id":"OG002","title":"TOTVI Not Randomized"},{"description":"All eligible children with ALL who are treated with risk-directed therapy.","id":"OG003","title":"All Eligible Patients in TOTXV"}],"paramType":"NUMBER","populationDescription":"All eligible patients entered on TOTXVI will be included in these analyses, as appropriate. Infants will be excluded from the Total XVI for comparisons with TOTXV as only children at least one year of age at diagnosis were treated on Total XV.","reportingStatus":"POSTED","timeFrame":"For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years","title":"Probability of Overall Survival","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}